NeuClone’s Trastuzumab Trial Succeeds
Reports Successful Phase I Trial For NeuCeptin Trastuzumab Biosimilar
NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.
You may also be interested in...
After extensive pre-clinical testing, NeuClone has commenced dosing in a Phase I clinical trial for its Stelara biosimilar candidate, NeuLara.
Armas has kicked off 2020 with the launch of four generic injectables in the US.